文献速递神经核医学肿瘤 PET/CT

淀粉样蛋白PET对痴呆鉴别诊断的增量价值:与临床诊断及FDG PET比较

Amyloid imaging for differential diagnosis of dementia: incremental value compared to clinical diagnosis and [18F]FDG PET.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2018-08-10

研究纳入84例记忆门诊中诊断为重度神经认知障碍(DSM-5)的连续患者,均接受[18F]FDG与[11C]PIB PET联合检查。披露淀粉样蛋白PET结果后,临床诊断和[18F]FDG PET诊断分别有23%和18%的患者发生改变,两者一致性从62%升至86%(p < 0.001);临床诊断准确率从71%升至89%(p < 0.01),[18F]FDG PET诊断准确率从76%升至94%(p < 0.001)。结论认为淀粉样蛋白PET在临床和[18F]FDG PET诊断之外提供显著增量诊断价值,但需进一步研究明确额外[18F]FDG PET扫描的作用。

要点

  • 披露淀粉样蛋白PET后,23%的临床诊断和18%的[18F]FDG PET诊断发生改变。
  • 临床与[18F]FDG PET诊断一致性从62%升至86%(p < 0.001)。
  • 诊断准确率:临床从71%升至89%(p < 0.01),[18F]FDG PET从76%升至94%(p < 0.001)。

核心结论

  • 淀粉样蛋白PET在临床诊断和[18F]FDG PET诊断之外提供显著的增量诊断价值。
  • 鉴于临床联合淀粉样蛋白PET评估具有高诊断准确率,需进一步研究明确额外[18F]FDG PET扫描在这些患者中的作用。

研究设计与样本

  • 在真实记忆门诊人群中验证淀粉样蛋白PET在临床诊断和[18F]FDG PET之外的增量诊断价值。
  • 138例连续认知障碍患者接受[18F]FDG与[11C]PIB PET联合检查,其中84例按DSM-5诊断为重度神经认知障碍并纳入分析。
  • 基线临床和[18F]FDG PET诊断分别在有无淀粉样蛋白PET结果的情况下独立建立,并二分为AD或非AD障碍。
  • 以扩展随访后(PET后2.4 ± 1.3年)的跨学科共识诊断作为参考标准评估诊断准确率。

主要发现

  • 披露淀粉样蛋白PET结果后,临床诊断在23%的患者中发生改变,[18F]FDG PET诊断在18%的患者中发生改变。
  • 临床与[18F]FDG PET诊断之间的一致性从62%升至86%(p < 0.001)。
  • 临床诊断准确率从71%升至89%(p < 0.01),[18F]FDG PET诊断准确率从76%升至94%(p < 0.001)。
  • 淀粉样蛋白PET的附加价值在发病年龄和与适当使用标准的一致性方面较为均匀。

局限性

  • 需进一步研究明确额外[18F]FDG PET扫描在这些患者中的作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Cerebral beta-amyloid and regional glucose metabolism assessed by positron emission tomography (PET) are used as diagnostic biomarkers for Alzheimer's disease (AD). The present study validates the incremental diagnostic value of amyloid PET in addition to clinical diagnosis and [18F]FDG PET in a real-life memory clinic population. METHODS: Of 138 consecutive patients with cognitive impairment who received combined [18F]FDG and [11C]PIB PET, 84 were diagnosed with major neurocognitive disorder (DSM-5) and included. Baseline clinical and [18F]FDG PET diagnoses were independently established with and without access to amyloid PET results and were dichotomized into AD or non-AD disorders. The incremental value of amyloid PET was evaluated in terms of: (1) the change in clinical and [18F]FDG PET diagnoses, (2) the change in agreement between clinical and [18F]FDG PET diagnoses, and (3) diagnostic accuracy using an interdisciplinary consensus diagnosis after an extended follow-up (2.4 ± 1.3 years after PET) as the reference. RESULTS: After disclosure of the amyloid PET results, clinical and [18F]FDG PET diagnoses changed in 23% and 18% of patients, respectively, and agreement between both ratings increased from 62% to 86% (p < 0.001). The accuracy of clinical and [18F]FDG PET diagnoses improved from 71% to 89% (p < 0.01) and from 76% to 94% (p < 0.001), respectively. The additional value of amyloid PET was rather uniform in relation to age at onset and consistency with appropriate use criteria. CONCLUSION: Amyloid PET provides significant incremental diagnostic value beyond clinical and [18F]FDG PET diagnoses of AD. Given the high diagnostic accuracy of combined clinical and amyloid PET assessment, further studies are needed to clarify the role of an additional [18F]FDG PET scan in these patients.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Hellwig S, Frings L, Bormann T, et al. Amyloid imaging for differential diagnosis of dementia: incremental value compared to clinical diagnosis and [18F]FDG PET. Eur J Nucl Med Mol Imaging. 2018. PMID: 30094462. doi:10.1007/s00259-018-4111-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。